Mid Year In Review Multiple Sclerosis 2018

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

By

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

By

Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Certain Comorbidities More Common in People With Multiple Sclerosis

Certain Comorbidities More Common in People With Multiple Sclerosis

By

The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

By

Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

By

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

By

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

By

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

By

A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis

By

Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

By

Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

Combined Exercise Training Increases BDNF in Relapsing-Remitting MS

By

The effect of 8 weeks of combined exercise training on serum BDNF concentration was examined in patients with relapsing-remitting multiple sclerosis.

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

Multiple Sclerosis Drug Zinbryta Withdrawn From the Market

By

Daclizumab, an interleukin-2 (IL-2) receptor blocking antibody, was approved in May 2016 to treat adults with relapsing forms of MS.

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

By

The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

By

Vitamin D deficiency is a risk factor for multiple sclerosis.

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

By

Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.

Case: High-Dose Biotin Leading to Pseudohyperthyroidism in Multiple Sclerosis

Case: High-Dose Biotin Leading to Pseudohyperthyroidism in Multiple Sclerosis

By

A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.

Stable Disability in Progressive Multiple Sclerosis With Teriflunomide

Stable Disability in Progressive Multiple Sclerosis With Teriflunomide

By

A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.

Multiple Sclerosis Development in Two Teens After HPV Vaccination

Multiple Sclerosis Development in Two Teens After HPV Vaccination

By

Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.

Predicting MS in Patients With Clinically Isolated Syndrome: MAGNIMS vs McDonald Criteria

Predicting MS in Patients With Clinically Isolated Syndrome: MAGNIMS vs McDonald Criteria

By

Researchers sought to compare 2010 McDonald and MAGNIMS criteria for predicting conversion to MS from clinically isolated syndrome.

Oral, IV Methylprednisolone Show Similar Benefits for Multiple Sclerosis Relapse

Oral, IV Methylprednisolone Show Similar Benefits for Multiple Sclerosis Relapse

By

While both intravenous and oral administrations of methylprednisolone showed similar efficacy, the investigators noted that oral administration may be more tolerable and cost-effective.

Sign Up for Free e-newsletters



CME Focus